Canada - English - Health Canada

sanofi-aventis canada inc - tiaprofenic acid - capsule (sustained-release) - 300mg - tiaprofenic acid 300mg - other nonsteroidal antiimflammatory agents

United States - English - NLM (National Library of Medicine)

amd medicom inc - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion .0272 g in 1 g - amd medicom inc. denticare pro-foam 2.72% topical sodium fluoride foam (1.23% fluoride ions) raspberry 4.4 oz / 125 g ndc 64778-0378-1 npn 80009738 rx only in us item code 10037-rb

United States - English - NLM (National Library of Medicine)

amd medicom inc - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.0272 g in 1 g - indications: topical anti-caries preparation directions: - following prophylaxis treatment, fill ¼ of tray with foam - to dispense, shake bottle vigorously then invert applicator 180° downward to the bottom of the tray - insert tray, have patient bite down lightly for a minimum of 60 seconds, up to 4 minutes - remove tray and have patient expectorate excess advise patient not to eat, drink or rinse for 30 minutes after the treatment medicinal ingredients: fluoride ions 1.23% w/w (from 2.72% w/w sodium fluoride)

United States - English - NLM (National Library of Medicine)

amd medicom inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.0272 g in 1 g - indications: topical anti-caries preparation directions: - following prophylaxis treatment, fill ¼ of tray with foam - to dispense, shake bottle vigorously then invert applicator 180° downward to the bottom of the tray - insert tray, have patient bite down lightly for a minimum of 60 seconds, up to 4 minutes - remove tray and have patient expectorate excess advise patient not to eat, drink or rinse for 30 minutes after the treatment medicinal ingredients: fluoride ions 1.23% w/w (from 2.72% w/w sodium fluoride)

United States - English - NLM (National Library of Medicine)

amd medicom inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.0272 g in 1 g - indications: topical anti-caries preparation directions: - following prophylaxis treatment, fill ¼ of tray with foam - to dispense, shake bottle vigorously then invert applicator 180° downward to the bottom of the tray - insert tray, have patient bite down lightly for a minimum of 60 seconds, up to 4 minutes - remove tray and have patient expectorate excess advise patient not to eat, drink or rinse for 30 minutes after the treatment medicinal ingredients: fluoride ions 1.23% w/w (from 2.72% w/w sodium fluoride)

United States - English - NLM (National Library of Medicine)

amd medicom inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.0272 g in 1 g - indications: topical anti-caries preparation directions: - following prophylaxis treatment, fill ¼ of tray with foam - to dispense, shake bottle vigorously then invert applicator 180° downward to the bottom of the tray - insert tray, have patient bite down lightly for a minimum of 60 seconds, up to 4 minutes - remove tray and have patient expectorate excess advise patient not to eat, drink or rinse for 30 minutes after the treatment medicinal ingredients: fluoride ions 1.23% w/w (from 2.72% w/w sodium fluoride)

United States - English - NLM (National Library of Medicine)

amd medicom inc. - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - fluoride ion 0.0272 g in 1 g - indications: topical anti-caries preparation directions: - following prophylaxis treatment, fill ¼ of tray with foam - to dispense, shake bottle vigorously then invert applicator 180° downward to the bottom of the tray - insert tray, have patient bite down lightly for a minimum of 60 seconds, up to 4 minutes - remove tray and have patient expectorate excess advise patient not to eat, drink or rinse for 30 minutes after the treatment medicinal ingredients: fluoride ions 1.23% w/w (from 2.72% w/w sodium fluoride)

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - clindamycin palmitate hydrochloride (unii: vn9a8jm7m7) (clindamycin - unii:3u02el437c) - clindamycin palmitate hydrochloride 75 mg in 5 ml - cleocin pediatric (clindamycin palmitate hcl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the warning box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and ge

United States - English - NLM (National Library of Medicine)

greenstone llc - clindamycin palmitate hydrochloride (unii: vn9a8jm7m7) (clindamycin - unii:3u02el437c) - clindamycin 75 mg in 5 ml - clindamycin palmitate hcl is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin‑allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometri

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - clindamycin palmitate hydrochloride (unii: vn9a8jm7m7) (clindamycin - unii:3u02el437c) - clindamycin 75 mg in 5 ml - cleocin pediatric (clindamycin palmitate hcl) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and